Processing...
Clinical Trials for Melanoma
Search
Search
There are 187 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
187 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced solid tumors driven by MAPK pathway alterations, including cohorts for NRAS‑mutant melanoma, BRAF‑altered melanoma/other tumors, KRAS/NRAS‑mutant non‑melanoma cancers, and BRAF‑altered glioma, receive once‑daily oral NST‑628. NST‑628 is an investigational, brain‑penetrant pan‑RAF/MEK molecular glue that stabilizes inactive RAF–MEK complexes to block MEK/ERK signaling; prior BRAF/MEK inhibitor exposure is excluded in expansion cohorts.
ClinicalTrials.gov ID: NCT06326411
HealthScout AI summary: Adults with unresectable stage III/IV melanoma (ECOG 0–1), including PD‑1–naïve, previously treated, or PD‑1–refractory cohorts, receive nivolumab plus hydroxychloroquine (an autophagy/lysosomal inhibitor) or nivolumab/ipilimumab plus hydroxychloroquine. Aims include defining HCQ dose with PD‑1/CTLA‑4 blockade and assessing response to nivolumab+HCQ, with key exclusions for active severe autoimmune disease, unstable CNS disease, and significant comorbidities.
ClinicalTrials.gov ID: NCT04464759
HealthScout AI summary: Adults with metastatic or unresectable BRAF V600–mutant melanoma who are stable on or have progressed after prior BRAF/MEK therapy receive standard dabrafenib/trametinib or encorafenib/binimetinib with added nilotinib. Nilotinib (a BCR-ABL/c-KIT/PDGFR tyrosine kinase inhibitor) is dose-escalated to assess safety, pharmacokinetics, and preliminary activity of this triplet strategy; treated, stable brain metastases allowed.
ClinicalTrials.gov ID: NCT04903119
HealthScout AI summary: Adults with measurable, biopsy-accessible stage III (macroscopic nodal) or stage IV melanoma, ECOG 0–1, and no prior PD‑1/PD‑L1 or CTLA‑4 therapy receive ipilimumab plus nivolumab combined with CBL0137, a non-genotoxic DNA intercalator that traps FACT to activate p53 and suppress NF‑κB/HSF1/MYC. Excludes active autoimmune disease or need for immunosuppression; serial biopsies and blood draws required.
ClinicalTrials.gov ID: NCT05498792
HealthScout AI summary: Adults with unresectable stage III–IV melanoma (ECOG 0–2), including PD-1–naïve metastatic patients or those with stable/partial response on ongoing PD-1 after ≥12 weeks and prior adjuvant checkpoint or BRAF/MEK allowed; excludes active diabetes requiring meds, active CNS disease, significant immunosuppression, or autoimmune disease needing systemic therapy. Patients receive pembrolizumab alone or pembrolizumab plus metformin (AMPK activator/mitochondrial complex I inhibitor aimed at reversing T-cell metabolic insufficiency) to assess immunometabolic and clinical benefit.
ClinicalTrials.gov ID: NCT03311308
HealthScout AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) after standard therapy failure; phase 1 tests oral GIM‑531 monotherapy (including NSCLC, TNBC, platinum‑resistant ovarian, and AKT3‑altered tumors), and phase 2 treats melanoma, NSCLC, or RCC that progressed on anti‑PD‑1 with continued anti‑PD‑1 plus GIM‑531. GIM‑531 is a first‑in‑class, Treg‑selective small‑molecule inhibitor linked to AKT3/PI3K–AKT pathway modulation to suppress Tregs and potentially restore antitumor immunity.
ClinicalTrials.gov ID: NCT06425926
HealthScout AI summary: Adults with metastatic or unresectable cutaneous melanoma progressing after prior anti–PD-1/PD-L1 therapy, and expansion cohorts including NSCLC, HNSCC, and esophageal cancer, receive PF-08046031 monotherapy, a CD228 (melanotransferrin)–targeted MMAE antibody–drug conjugate. Excludes active CNS disease, prior CD228-targeted therapy, prior vedotin/MMAE ADCs or taxanes for advanced disease, and non-cutaneous melanoma.
ClinicalTrials.gov ID: NCT06799533
HealthScout AI summary: Adults with metastatic cutaneous melanoma, including those refractory to prior PD-1/PD-L1 therapy and with at least one resectable lesion for TIL harvest, receive non-myeloablative lymphodepletion followed by autologous TIL infusion and high-dose IL-2, with most eligible patients also receiving pembrolizumab (anti–PD-1) given peri- and post-infusion. Patients with controlled small asymptomatic brain metastases may enroll; key exclusions include significant autoimmune disease, active infections, major cardiopulmonary compromise, and prior severe immune-related toxicities to PD-1/PD-L1 agents for the pembrolizumab arm.
ClinicalTrials.gov ID: NCT02621021
HealthScout AI summary: This trial evaluates the safety and maximum tolerated dose of INBRX-106, a hexavalent OX40 agonist antibody, both alone and in combination with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors, including NSCLC, melanoma, and head and neck squamous cell carcinoma, who have progressed on standard therapies.
ClinicalTrials.gov ID: NCT04198766
HealthScout AI summary: This trial targets adult patients with advanced solid tumors, including NSCLC, melanoma, liposarcoma, leiomyosarcoma, and SCCHN, who have exhausted standard treatments. It evaluates OR2805, a monoclonal antibody targeting CD163 to modulate tumor-associated macrophages, administered alone or with cemiplimab or docetaxel.
ClinicalTrials.gov ID: NCT05094804